Changelog Master Feed From GitLab to Kilo Code (Changelog Interviews #672)
13 snips
Jan 7, 2026 
In this discussion, Sid Sijbrandij, the founder of GitLab and current CEO of Kilo.ai, shares his inspiring journey after a bone cancer diagnosis. He talks about combining treatments and innovative diagnostics from international sources to enhance his recovery. Sid also dives into his new venture, Kilo, which aims for an all-in-one coding platform that accelerates engineering productivity using agentic parallelism. He emphasizes the vital role of AI in intersecting fields and offers insights on the future of tech while managing health challenges.
AI Snips
Chapters
Transcript
Episode notes
Rapid Response To A Life-Threatening Diagnosis
- Sid discovered a six centimeter tumor in his spine and underwent surgery, radiation, chemo, and an experimental single-patient IND treatment.
- He traveled globally for diagnostics and combined treatments to scale options for others.
First Principles Guide Personalized Combinations
- Combining treatments can be justified by first principles when large trials for combinations lack commercial incentive.
- Multidisciplinary boards and histochemistry help safely combine therapies without standard trial evidence.
Therapeutic Ladder Buys Time
- Sid currently has no detectable cancer but assumes microscopic disease remains and maintains a therapeutic ladder of about 30 medicines.
- He develops multiple drugs and diagnostics simultaneously to keep treatment options open.